
The Uromigos
The UromigosAudio
- Format:
- Podcast
- New episodes:
- Daily
- Typical length:
- about 40 minutes
- Latest episode:
About this show
Broadcasting the latest developments in GU cancer
Hosted by Brian Rini and Tom Powles
Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
Covers: oncology, genitourinary cancer, renal cell carcinoma, prostate cancer, bladder cancer, antibody drug conjugates, cancer immunotherapy, circulating tumor dna
Show details and episodes come from the publisher's public feed at anchor.fm. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
The Uromigos is a podcast on the latest developments in genitourinary cancer, hosted by Brian Rini and Tom Powles. Recent episodes cover T cell engagers in kidney cancer, doublet therapy in renal cell carcinoma, prostate cancer sequencing, and antibody drug conjugates and ctDNA in bladder cancer.
Cosmos
Similar in subject
- BackTable Urology
Both cover: bladder cancer, prostate cancer - Oncology Brothers: Practice-Changing Cancer Discussions
Both cover: genitourinary cancer, oncology - Two Onc Docs
Both cover: prostate cancer, oncology
Similar shows
Explore more
Episodes
Episode 520: ESMO 2026 Preview
· 54 min
Silke, Brian and Tom preview the major data to be presented at ESMO 2026
Not rated yetEpisode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC?
· 33 min
Shilpa Gupta joins us to discuss an X poll revealing equipoise about treatment approaches to resected high-risk upper tract urothelial cancer (UTUC).
Not rated yetEpisode 518: PSMAddition in Clinical Practice
· 31 min
Rob Dreicer joins the show to discuss the FDA approval of Lutetium Lu 177 in the mHSPC space and how to contextualize the benefit/risk
Not rated yetEpisode 517: Casdatifan Clinical Data in RCC and Translational Correlates
· 40 min
Toni Choueiri joins Brian and Tom to discuss a recent Nature paper regarding the novel HIF inhibitor, casdatifan, and biomarkers of response.
Not rated yetEpisode 516: The Influence of Hypoxia on Response and Resistance in RCC
· 47 min
Ari Hakimi and Lyn Voung from MSKCC join Brian and Tom to discuss their recent Cancer Cell paper exploring the mechanistic impact of TKI-induced hypoxia on immune response in RCC.
Not rated yetEpisode 515: PROTEUS - A Reflection on the Data and Controversies with Neha Vapiwala
· 43 min
Brian and Tom invite Neha Vapiwala, a Radiation Oncologist, to discuss areas of consensus and controversy from the PROTEUS trial of ADT +/- apalutamide in high-risk localized prostate cancer.
Not rated yetEpisode 514: Artificial Intelligence in Cancer Drug Development
· 40 min
Travis Zack, CMO of Open Evidence, joins Brian and Tom to discuss the emergence of AI across the spectrum on cancer, drug development and application of data.
Not rated yetEpisode 513: Trials and Tribulations of Investigator-initiated Research
· 25 min
Bishoy Faltas joins Brian and Tom to discuss his IIT in bladder cancer. The intended discussion of the trials turned into an insightful discussion on the challenges and learning opportunities of IITs.
Not rated yetEpisode 512: ENZA-P Nature Medicine translational data
· 31 min
In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.
Not rated yetEpisode 510: ADCs in Prostate Cancer
· 30 min
Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.
Not rated yetEpisode 509: ASCO 2026 Review
· 55 min
This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent studies, controversies, and future directions in GU oncology.
Not rated yetEpisode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer
· 39 min
Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.
Not rated yetEpisode 507: ASCO 2026 - TALAPRO-3
· 41 min
Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.
Not rated yetEpisode 506: ASCO 2026 - How do we measure quality of life in GU patients?
· 19 min
This panel discussion podcast with Brian, Tom, Peter O'Donnell and Elizabeth Nally explores the complexities of measuring quality of life in cancer clinical trials, highlighting recent data, patient perspectives, and innovative approaches to assessment. Experts discuss the limitations of current tools, the importance of long-term follow-up, and future directions for integrating patient-centered metrics.
Not rated yetEpisode 505 : ASCO 2026 - RAMPART
· 29 min
James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.
Not rated yetEpisode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer
· 40 min
This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts discuss efficacy, safety, biomarkers, and future directions in bladder cancer treatment.
Not rated yetEpisode 499: APCCC 2026 - Radioligands in Prostate Cancer
· 37 min
This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prostate cancer treatment. Gain a deep understanding of current practices, challenges, and future directions in radiopharmaceuticals.
Not rated yetEpisode 503: ASCO 2026 Preview
· 1 hr 22 min
Silke joins Brian and Tom to discuss what to look for in GU cancers at ASCO 2026
Not rated yetEpisode 502: AUA 2026 and FDA bladder cancer meeting
· 35 min
In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of drug approvals, the importance of randomized trials, and the emerging data on Deltalimagene, a non-viral gene therapy. The conversation highlights the complexities of treatment options, the need for robust clinical trials, and the future landscape of bladder cancer therapies
Not rated yetEpisode 501: APCCC 2026 - Biochemically-relapsed Prostate cancer
· 19 min
Chuck Ryan from MSKCC joins us in Lugano for the final podcast from APCCC to talk about the ever-evolving space of BCR in prostate cancer.
Not rated yet